Ahmet Dirican: Apixaban vs Rivaroxaban in Acute VTE
Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X about a recent article by Lana A. Castellucci et al, published in The New England Journal of Medicine:
”New NEJM trial: Apixaban vs Rivaroxaban in acute VTE
Clinically relevant bleeding:
Apixaban 3.3%
Rivaroxaban 7.1%
RR 0.46
- Similar efficacy for recurrent VTE
- Significantly lower bleeding with apixaban
However, an important limitation: Cancer-associated thrombosis patients were excluded from the trial.
So there is no direct evidence in oncology patients. Still, in daily oncology practice — especially in patients with higher bleeding risk — this signal may be worth keeping in mind when choosing between DOACs.”
Title: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Authors: Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn, Benoit Côté, Sam Schulman, Kerstin de Wit, James Douketis, Deepa Suryanarayan, Tony Wan, Erik Yeo, Genevieve Le Templier, Huyen A. Tran, Abbey Willcox, Helen J. Crowther, Ritam Prasad, Sudeep Shivakumar, Etimbuk Umana, Fionnuala Ni Ainle, Tobias Tritschler, Stefano Barco, Jean-Philippe Galanaud, Marc Blondon, Lisa Baumann Kreuziger, Susan Solymoss, Clive Kearon, Erin Thomas, Tim Ramsay, Gregoire Le Gal, Marc Rodger
Read the Full Article on The New England Journal of Medicine
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 10, 2026, 09:05Wolfgang Miesbach: Moving from Bleed Control to Comprehensive Joint Health
-
Oct 10, 2026, 07:59Leila Caroline Souza Reis: Enoxaparin Dosing for VTE Prevention in Adults With Obesity
-
Oct 10, 2026, 07:41Adeeb Bazuhair: New Evidence for Catheter Directed Thrombolysis in Acute PE
-
Oct 10, 2026, 07:22Poppy Clarke: Turning Steps Into Support for Thrombosis Awareness
-
Oct 10, 2026, 07:12Hamzah Khan: The Role of Genuine Curiosity in Driving High-Impact Academic Research
-
Oct 10, 2026, 06:58Nita Radhakrishnan: Turning Evidence Into Action for Hemophilia Care in India
-
Oct 10, 2026, 06:48Nutan Kaushik: HemeNext 2.0 Brings Global Perspectives to Hematology
-
Oct 10, 2026, 06:43Suthesh Sivapalaratnam: Advancing Bleeding Disorder Care at EHC 2026
-
Oct 10, 2026, 02:38Brianne D.: Sex Differences in RIPK1 Signaling Following Intracerebral Hemorrhage